On January 13, 2026, several prominent Indian companies, including Tata Consultancy Services (TCS), HCLTech, Adani Energy Solutions, and Biocon, are drawing significant market attention due to recent corporate announcements and Q3 FY26 earnings. TCS is in focus following its Q3 results, which revealed an 11.70% decline in net profit quarter-on-quarter, alongside a 2% rise in revenue. The company also confirmed ongoing job cuts as part of a restructuring plan, with approximately 30,000 employees having exited in the last six months, though it is simultaneously increasing fresher hiring in AI-focused areas. An interim dividend of ₹11 per share and a special dividend of ₹46 per share were also declared. HCLTech also reported its Q3 FY26 performance, showcasing strong revenue growth with USD revenue at $3.8 billion, a 4.2% constant currency growth quarter-on-quarter, and new bookings worth $3 billion. However, its net profit saw a 3.70% dip, partly attributed to the impact of new labor codes. The company announced an interim dividend of ₹12 per share. Despite onboarding nearly 2,852 freshers, HCLTech experienced a slight net workforce reduction of 261 employees in the quarter, influenced by attrition and strategic rationalization. Notably, HCLTech is offering higher salaries for freshers proficient in advanced AI and digital skills. Adani Energy Solutions has been in the news for substantial operational growth, expanding its transmission network to 27,901 circuit kilometers and boosting its order book to ₹77,787 crore in Q3 FY26. The company also made strides in smart metering, installing 18.88 lakh new meters and accumulating a total of 92.5 lakh meters, with a potential revenue of ₹29,519 crore from its order book of 2.46 crore units. Additionally, a subsidiary of Adani Green Energy signed agreements to supply hybrid solar and wind power to Asahi India Glass. Biocon is attracting investor interest after launching a Qualified Institutional Placement (QIP) worth ₹4,150 crore, which was reportedly oversubscribed, largely by domestic mutual funds. Its subsidiary, Biocon Pharma, secured US FDA approval for a generic version of everolimus tablets. The company has scheduled a board meeting for February 12, 2026, to review its Q3 FY26 financial results. This widespread activity among major Indian corporations makes them key stocks for investors to monitor today.